Cargando…

Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey

The ICH E9(R1) addendum on Estimands and Sensitivity Analyses in Clinical Trials has introduced a new estimand framework for the design, conduct, analysis, and interpretation of clinical trials. We share Pharmaceutical Industry experiences of implementing the estimand framework in the first two year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fletcher, C., Hefting, N., Wright, M., Bell, J., Anzures-Cabrera, J., Wright, D., Lynggaard, H., Schueler, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035309/ https://www.ncbi.nlm.nih.gov/pubmed/35462609 http://dx.doi.org/10.1007/s43441-022-00402-3

Ejemplares similares

Why estimands are needed to define treatment effects in clinical trials
por: Keene, Oliver N., et al.
Publicado: (2023)

Principles and recommendations for incorporating estimands into clinical study protocol templates
por: Lynggaard, Helle, et al.
Publicado: (2022)

Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder
por: Polverejan, Elena, et al.
Publicado: (2023)

Estimands for factorial trials
por: Kahan, Brennan C., et al.
Publicado: (2022)

Understanding estimands
por: Gogtay, Nithya Jaideep, et al.
Publicado: (2021)

Commentary: Estimands in cluster trials: thinking carefully about the target of inferenceand the consequences for analysis choice
por: Hemming, Karla, et al.
Publicado: (2022)

Translating questions to estimands in randomized clinical trials with intercurrent events
por: Stensrud, Mats J., et al.
Publicado: (2022)

Estimands: bringing clarity and focus to research questions in clinical trials
por: Clark, Timothy Peter, et al.
Publicado: (2022)

Rethinking intercurrent events in defining estimands for tuberculosis trials
por: Pham, Tra My, et al.
Publicado: (2022)

Estimands and Complex Innovative Designs
por: Collignon, Olivier, et al.
Publicado: (2022)

Estimands in epigenome-wide association studies
por: Kruppa, Jochen, et al.
Publicado: (2021)

Estimands—What they are and why they are important for pharmacometricians
por: Akacha, Mouna, et al.
Publicado: (2021)

Estimands in published protocols of randomised trials: urgent improvement needed
por: Kahan, Brennan C., et al.
Publicado: (2021)

Estimands in cluster-randomized trials: choosing analyses that answer the right question
por: Kahan, Brennan C, et al.
Publicado: (2022)

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
por: Aroda, Vanita R., et al.
Publicado: (2019)

Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods
por: Olarte Parra, Camila, et al.
Publicado: (2022)

Eliminating Ambiguous Treatment Effects Using Estimands
por: Kahan, Brennan C, et al.
Publicado: (2023)

Re-randomisation trials in multi-episode settings: Estimands and independence estimators
por: Kahan, Brennan C, et al.
Publicado: (2022)

Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions
por: Kahan, Brennan C., et al.
Publicado: (2020)

Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine—That is the Estimand
por: van Eijk, Ruben P.A., et al.
Publicado: (2022)

Some considerations on target estimands for health technology assessment
por: Remiro‐Azócar, Antonio
Publicado: (2022)

Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial
por: Weir, Isabelle R, et al.
Publicado: (2023)

Analytical approaches and estimands to take account of missing patient-reported data in longitudinal studies
por: Bell, Melanie L, et al.
Publicado: (2019)

Think different, act different for a new journey!
por: Melath, Anil
Publicado: (2018)

Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands
por: Cro, Suzie, et al.
Publicado: (2022)

Estimands to quantify prolonged hospital stay associated with nosocomial infections
por: Wolkewitz, Martin, et al.
Publicado: (2019)

Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand
por: Pétavy, Frank, et al.
Publicado: (2020)

Statistical methods and graphical displays of quality of life with survival outcomes in oncology clinical trials for supporting the estimand framework
por: Sakamaki, Kentaro, et al.
Publicado: (2022)

Starting a conversation about estimands with public partners involved in clinical trials: a co-developed tool
por: Cro, Suzie, et al.
Publicado: (2023)

A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
por: Mitroiu, M., et al.
Publicado: (2020)

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
por: Wharton, Sean, et al.
Publicado: (2021)

What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
por: Lawrance, Rachael, et al.
Publicado: (2020)

Portal through mathematics: journey to advanced thinking
por: Ivanov, O A
Publicado: (2017)

University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (afternoon panel session)
por: Little, Roderick J, et al.
Publicado: (2019)

Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study
por: Rehal, Sunita, et al.
Publicado: (2023)

PNS250 How to Deal with COVID-19-Related Intercurrent Events on Trial Estimands for Patient-Reported Outcomes (PRO) Objectives
por: Skaltsa, K., et al.
Publicado: (2020)

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018)

FDA, CE mark or something else?—Thinking fast and slow
por: Mishra, Sundeep
Publicado: (2017)

Ginseng: A bibliometric analysis of 40-year journey of global clinical trials
por: Chen, Weijie, et al.
Publicado: (2020)

New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
por: Jimeno, J., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_4fsn9gbabfsrrjrbdfjltr9qgb